The University and group of Physics in Radiation Oncology at Massachusetts General Hospital are collaborating to find solutions for more effective radiation therapy.

The Medical research and Biophysics research group at the School of Science at the University of Navarra and the Radiation Oncology research group at Massachusetts General Hospital —affiliated with School of Medicine —have signed a partnership agreement conduct research aimed at developing more personalized radiation therapy.

According to Javier Burguete, coordinator of the group researcher of the University of Navarra, the main goal of this agreement is to develop a model adapted to each patient by combining the different approaches of work proposed by both groups from the USA and Navarra. "The US group has developed a generic model based on statistical parameters of the population. Our group has developed a procedure to obtain in a personalized way the blood circulation of large vessels, based on MRI measurements".

This agreement, which has a five-year term and is renewable, facilitates the exchange doctoral students and researchers between the two institutions. The partnership when Carlos Huesa, a professor at the School of Science a postdoctoral fellowship at Harvard University more than a year ago. Marina García-Cardosa, a doctorate student doctorate the University of Navarra, began her fellowship in December thanks to this agreement.

"The goal is to improve the treatments that patients receive, and to move closer towards a completely personalized treatment. Carlos Huesa's work opens the door to obtaining a better estimate of the dose received in the case of treatments using radioactive spheres, and in the case of Marina García-Cardosa it opens the door to reducing the radiation received by the circulating blood".

For Burguete this research may have a direct application in those patients treated with these therapies and is intended to reduce the side effects of radiation doses. "Reducing the dose received by healthy organs is crucial for the best possible quality of life and prognosis. Our work provides a evaluation of the dose received by the blood, which is increasingly considered an organ at risk," he concludes.